Compare ADMA Biologics Inc (ADMA) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Microchip Technology Inc. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Microchip Technology Inc. trades at $85.24 (market cap $45.69B). The key difference: Microchip Technology Inc. is far larger — about 21.5× ADMA Biologics Inc's market cap, and Microchip Technology Inc. pays a 2.16% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MCHP | |
|---|---|---|
Market Cap | $2.13B | $45.69B |
Sector | Health | Technology |
52-Week High | $20.38 | $102.97 |
52-Week Low | $7.60 | $49.02 |
Enterprise Value | $2.20B | $50.99B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Microchip Technology (MCHP) trades at $84.15, down 0.58% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 exceeding the $0.505 forecast. The company benefits from AI-driven semiconductor demand, aerospace and defense growth, and new product launches like the TimePictra 12 platform. However, 2025 saw a net loss of $500,000 on revenue of $4.40 billion, though 2026 projections indicate a return to profitability with a 4.88% net margin.
MCHP presents a mixed outlook: robust growth catalysts in AI and aerospace contrast with high valuation multiples (P/E of 398.14) and recent profitability challenges. The consensus price target of $115.45 suggests 37% upside, but investors face risks from debt levels and market volatility. The stock's near-term direction hinges on execution of its Q2 2026 earnings and sustained demand in key sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
